Company: LIMN
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001104659-25-010605
Chunk: 330

Company: Liminatus Pharma, Inc.
Filing Date: 2025-02-07
Form: 424B3
Chunk 330
---
 as Secretary; and (2) on July 27, 2022, the following actions occurred (i) the Sponsor changed its name from Tribe Arrow Holdings I LLC, to Iris Acquisition Holdings LLC, and (ii) Iris’s strategy to identify a target business was revised so that there is no restriction in the geographic location or business of targets we can pursue. However, with the change of management, we intended to prioritize (i) emerging markets followed by the United States and rest of Asia (excluding China and Hong Kong), and (ii) technology-led companies focused on essential sectors. The director and officer departures were not the result of any disagreement between us and such individuals on any matter relating to our operations, policies, or practices.

Effective July 26, 2022, the Iris Board appointed: (i) Sumit Mehta to serve as Iris’s Chief Executive Officer, (ii) Lisha Parmar to serve as Iris’s Chief Financial Officer, and (iii) Omkar Halady to serve as the Vice President of Iris. Also, Rohit Nanani was elevated from member to Chairman of the Iris Board.

On August 30, 2022, the Iris Board appointed Manish Shah to serve as a director until Iris’s next annual meeting of stockholders. On November 14, 2022, Duriya Farooqui resigned from the Iris Board, effective December 15, 2022.

On December 20, 2022, Iris filed with the Secretary of State of the State of Delaware the Extension Amendment to Iris’s amended and restated certificate of incorporation to change the date by which Iris

<div align='center'>177</div>

TABLE OF CONTENTS

must consummate a business combination from March 9, 2023 to June 9, 2023 (subject to an additional three month extension at the discretion of the Iris Board). Iris’s stockholders approved the Extension Amendment at the special meeting on December 20, 2022.

In connection with the special meeting, stockholders holding 26,186,896 shares of Iris Class A Common Stock properly exercised their right to redeem their shares (and did not withdraw their redemption) for cash at a redemption price of approximately $10.08 per share, for an aggregate redemption amount of $263,963,913. Following such redemptions, 1,413,104 shares of Iris Class A Common Stock remained outstanding in the trust.

On April 26, 2023, Dr. Shashibh